Karadeniz Technical University, Faculty of Medicine, Division of Intensive Care Medicine, Department of Chest Diseases, Trabzon, Turkey.
Health Sciences University, Samsun Training and Research Hospital, Clinic of Intensive Care Medicine, Samsun, Turkey.
Braz J Anesthesiol. 2022 Jan-Feb;72(1):29-36. doi: 10.1016/j.bjane.2021.03.022. Epub 2021 Apr 24.
The objective of this study was to investigate the use of early APRV mode as a lung protective strategy compared to conventional methods with regard to ARDS development.
The study was designed as a randomized, non-blinded, single-center, superiority trial with two parallel groups and a primary endpoint of ARDS development. Patients under invasive mechanical ventilation who were not diagnosed with ARDS and had Lung Injury Prediction Score greater than 7 were included in the study. The patients were assigned to APRV and P-SIMV + PS mode groups.
Patients were treated with P-SIMV+PS or APRV mode; 33 (50.8%) and 32 (49.2%), respectively. The P/F ratio values were higher in the APRV group on day 3 (p = 0.032). The fraction of inspired oxygen value was lower in the APRV group at day 7 (p = 0.011).While 5 of the 33 patients (15.2%) in the P-SIMV+PS group developed ARDS, one out of the 32 patients (3.1%) in the APRV group developed ARDS during follow-up (p = 0.197). The groups didn't differ in terms of vasopressor/inotrope requirement, successful extubation rates, and/or mortality rates (p = 1.000, p = 0.911, p = 0.705, respectively). Duration of intensive care unit stay was 8 (2-11) days in the APRV group and 13 (8-81) days in the P-SIMV+PS group (p = 0.019).
The APRV mode can be used safely in selected groups of surgical and medical patients while preserving spontaneous respiration to a make benefit of its lung-protective effects. In comparison to the conventional mode, it is associated with improved oxygenation, higher mean airway pressures, and shorter intensive care unit stay. However, it does not reduce the sedation requirement, ARDS development, or mortality.
本研究旨在探讨与传统方法相比,早期 APRV 模式作为一种肺保护策略,在 ARDS 发展方面的效果。
这是一项设计为随机、非盲、单中心、优效性试验,采用平行分组,主要终点为 ARDS 发展。纳入研究的患者为接受有创机械通气、尚未诊断为 ARDS 且肺损伤预测评分大于 7 的患者。患者被分配到 APRV 和 P-SIMV+PS 模式组。
患者分别接受 P-SIMV+PS 或 APRV 模式治疗;APRV 组 33 例(50.8%),P-SIMV+PS 组 32 例(49.2%)。APRV 组第 3 天的 P/F 比值更高(p=0.032)。APRV 组第 7 天的吸入氧分数更低(p=0.011)。P-SIMV+PS 组中 5 例(15.2%)患者在随访期间发展为 ARDS,APRV 组中 1 例(3.1%)患者发展为 ARDS(p=0.197)。两组在血管加压素/儿茶酚胺需求、成功拔管率和/或死亡率方面无差异(p=1.000、p=0.911、p=0.705)。APRV 组的 ICU 住院时间为 8 天(2-11 天),P-SIMV+PS 组为 13 天(8-81 天)(p=0.019)。
APRV 模式可安全用于外科和内科患者的选定人群,同时保留自主呼吸,以获得其肺保护作用。与传统模式相比,它与改善氧合、更高的平均气道压力和缩短 ICU 住院时间相关。然而,它并未减少镇静需求、ARDS 发展或死亡率。